title: Health care costs for schizophrenia patients started on olanzapine versus risperidone.
abstract: OBJECTIVE
  The change in direct medical costs for schizophrenia patients who were started on olanzapine or risperidone and who were privately insured was studied.
  
  
  METHODS
  A retrospective analysis of 1996-1999 data from the databases representing the health care experiences of individuals employed by large organizations and their dependents was performed. The sample included all individuals with a drug claim for olanzapine or risperidone, a claim with a schizophrenia diagnosis within 90 days of the drug claim, no claim for the same drug in the prior six months, and continuous health-plan enrollment for 12 months before and after the prescription.
  
  
  RESULTS
  The sample included 162 patients initiated on olanzapine and 119 patients initiated on risperidone. Demographic and clinical profiles were not significantly different between groups. Annual schizophrenia-related prescription and outpatient costs increased following initiation on olanzapine or risperidone compared with the pre-initiation period. This was partially offset by a decrease in inpatient expenditures. Olanzapine initiators had higher outpatient drug expenditures than risperidone initiators in the 12 months following initiation (adjusted means, $2105 versus $1934) (p < 0.05), but there was no significant difference between groups in total schizophrenia-related payments ($5251 versus $4950).
  
  
  CONCLUSIONS
  The total health care expenditure related to treating schizophrenia was similar between privately insured patients who were initiated on olanzapine and patients who were started on risperidone.
authors.affiliation: Outcomes Research and Econometrics, The Medstat Group, 4301 Connecticut Avenue NW, Suite 330, Washington, DC 20008, USA. patrusso4@earthlink.net
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Russo
authors.forename: Mark W
authors.initials: MW
authors.lastname: Smith
authors.forename: Madhav
authors.initials: M
authors.lastname: Namjoshi
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000191:economics / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000191:economics / Q000627:therapeutic use*; D016208:Databases, Factual; D005260:Female; D017048:Health Care Costs; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D012189:Retrospective Studies; D018967:Risperidone / Q000191:economics / Q000627:therapeutic use*; D012559:Schizophrenia / Q000145:classification / Q000188:drug therapy* / Q000191:economics
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine